Patient attitudes and understanding about biosimilars: an international cross-sectional survey.
OBJECTIVE
To understand the levels of awareness, usage, and knowledge of biosimilars among patients, caregivers, and the general population in the US and the European Union; perceptions of biosimilars compared to originator biologics; perceived benefits and drawbacks of clinical trials; and whether advocacy groups impact patients' willingness to try a biosimilar.


METHODS
An international survey was conducted which contained up to 56 closed-ended (requiring yes/no or ranking answers) and open-ended questions, depending on the population assigned. The survey was divided into distinct sections, including medication-class awareness, usage, and knowledge about biologic and biosimilar therapies; perceptions of clinical trials; and involvement in advocacy groups. Interviews were conducted in adults categorized as: 1) diagnosed: patients with inflammatory bowel disease including Crohn's disease and ulcerative colitis, rheumatoid arthritis, psoriasis, breast cancer, lung cancer, colorectal cancer, or non-Hodgkin's lymphoma; 2) diagnosed advocacy: individuals with these diseases who participated in patient support groups; 3) caregiver: has a loved one with these conditions and is involved in medical decisions; 4) general population: aged 18-64 years, without these conditions. Statistical analyses among groups within a region (US or EU) used column proportions test with a 95% confidence interval.


RESULTS
In all, 3,198 individuals responded. Awareness about biologic therapies was significantly higher in diagnosed, diagnosed advocacy, and caregiver groups (45%-78%) versus general population (27%; P<0.05). Across all groups, awareness of biosimilars was low; only 6% of the general population reported at least a general impression of biosimilars. Awareness was significantly higher in the diagnosed advocacy group (20%-30%; P<0.05). Gaps in knowledge about biosimilars included safety, efficacy, and access to these agents. Respondents had generally positive perceptions of clinical trials, although barriers to participation were identified.


CONCLUSIONS
An immediate need exists for patient education about biosimilars and clinical trials to ensure educated and informed decisions are made about biosimilar use.
Global Established Pharma Medicines Development Group, Pfizer Inc., New York, NY, USA.
Ira
I
Jacobs
Global Medical Affairs, Pfizer Inc., Collegeville, PA, USA.
Ena
E
Singh
Biotechnology Clinical Development, Pfizer Inc., Cambridge, MA, USA.
K Lea
KL
Sewell
Global Established Pharma Medicines Development Group, Pfizer Inc., New York, NY, USA.
Ahmad
A
Al-Sabbagh
Global Established Pharma Medicines Development Group, Pfizer Inc., New York, NY, USA.
Lesley G
LG
Shane
advocacy groups; biologic therapy; biosimilar; cancer; inflammatory disease; oncology; patient education; treatment